ACCESS & SUPPORT

Together with EXDENSUR Patient Support

Together with EXDENSUR is a program designed to help prescribed patients with tailored support when it comes to coverage, access, and affordability for EXDENSUR. We help navigate access challenges with the right resources and timely updates.

VISIT TOGETHER WITH EXDENSUR
GET PRINTABLE RESOURCES
Together with EXDENSUR logo

How can Together with EXDENSUR help your prescribed patients?

Coverage Support

We'll verify your patients' insurance coverage and help you understand their benefits.* We can also provide information regarding prior authorizations and appeal process.

Cost Support

We understand the importance of addressing treatment affordability for your patients, and we may be able to offer solutions to help eligible patients.

Patient Support

The dedicated Patient Navigator† is at the heart of our program, offering education, resources, and support.

  • *The information provided by Together with EXDENSUR is not a guarantee of coverage or payment.
  • †The Patient Navigator does not provide medical advice and is not a part of the patient's care team. Patients will be directed to their treating healthcare provider for questions about their disease or EXDENSUR treatment.

Get started together–help your patients enroll with the option that best fits their needs

Option 1 - Enroll online launch

You are guided through what information is needed to process the enrollment for your patient.

Option 2 - Print and fax picture_as_pdf

If you would like a downloadable form to fill out, use the link above. Fill out the enrollment form and confirm all required fields have been completed. Then fax it to 1-844-760-0940.

Pay as little as zero dollars for EXDENSUR

EXDENSUR Copay Program

The EXDENSUR Copay Program can provide assistance to eligible patients for their portion of administration fees up to $100 per administration, which counts toward the annual copay production maximum.

Patients may be eligible based on the following general eligibility criteria:

  • Patient must have a commercial medical or prescription insurance plan
  • Patient is a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands)
  • Patient is not eligible for or enrolled in a government funded program that provides prescription drug coverage§
ENROLL ONLINE
  • ‡Program annual maximums apply. Eligibility for the EXDENSUR Copay Program must be determined by the GSK Copay Program. Visit EXDENSURcopayprogram.com for information about eligibility and full program terms and conditions.
  • §Patients are not eligible for this program if they are covered by any federal or state prescription insurance program. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare. This may also include state pharmaceutical assistance programs and other federal or state plans not listed. Patients are also ineligible for this program if they are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients enrolled in a state- or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. Patients enrolled in private indemnity or HMO insurance plans that reimburse them for the entire cost of their prescription drugs are also not eligible. Residents of Massachusetts and Rhode Island are not eligible for reimbursement of administration fees. Patients’ out-of-pocket responsibilities for other related services, such as office visit copays, are not eligible for copay assistance.

Printable resources for you and your patients.

Together with EXDENSUR Brochure picture_as_pdf

Learn more about the Together with EXDENSUR program

EXDENSUR Billing and Coding Quick Reference Guide picture_as_pdf

Billing and coding details for HCPs prescribing EXDENSUR

EXDENSUR Patient Brochure picture_as_pdf

Information about EXDENSUR for patients

EXDENSUR Getting Started Guide picture_as_pdf

Learn about dosing and administering EXDENSUR to your patients

EXDENSUR Ordering Guide picture_as_pdf

Information on how to order EXDENSUR 

Indication & Safety Info

Indication

Important Safety Information

Indication

EXDENSUR is indicated for the add-on maintenance treatment of severe asthma, characterized by an eosinophilic phenotype, in adult and pediatric patients aged 12 years and older. EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus.

Important Safety Information

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, can occur following administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy.

Acute Asthma Symptoms or Deteriorating Disease
EXDENSUR should not be used to treat acute asthma symptoms or acute exacerbations.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage
Upon initiation of EXDENSUR therapy, do not abruptly discontinue systemic or inhaled corticosteroids. Reductions in corticosteroid dose, if appropriate, should be gradual and under the supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection
Patients with pre-existing helminth infections should be treated for their infection prior to initiation of EXDENSUR therapy. If patients become infected while receiving EXDENSUR and do not respond to anti-helminth treatment, discontinue EXDENSUR until the infection resolves.

ADVERSE REACTIONS

In patients receiving EXDENSUR, the most common adverse reactions (≥4%) were upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. Injection site reactions have also occurred. 

USE IN SPECIFIC POPULATIONS

The data in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of endogenous IgG antibodies and monoclonal antibodies, such as depemokimab-ulaa, across the placenta increases as pregnancy progresses and peaks during the third trimester.

EXDENSUR can cross the placenta during pregnancy and the presence of the YTE modification may prolong and increase exposure to the infant exposed in utero. The impact of transmission to the fetus should be considered. Pregnant women exposed to EXDENSUR, or their healthcare providers, should report EXDENSUR exposure by calling 1-888-825-5249.

Please see full Prescribing Information for EXDENSUR.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.